Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a 1,5-benzodiazepine with anticonvulsant properties. Unlike 1,4-benzodiazepines (e.g., diazepam), it has a unique chemical structure that may result in a more favorable therapeutic profile regarding sedation and tolerance.
## Primary Indications
Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients ≥2 years old. Off-label use includes management of other refractory epilepsy syndromes and acute anxiety.
## Adult Dosing
* **Initial Dose:** 10 mg/day.
* **Titration:** Increase at weekly intervals based on clinical response and tolerability.
* **Target/Maintenance Dose:** 20–30 mg/day, divided twice daily.
* **Maximum Dose:** 40 mg/day (doses >20 mg/day are generally given in two divided doses).
## Pediatric Dosing (≥2 years old)
Dosing is weight-based for patients weighing ≤30 kg:
* **Initial Dose:** 5 mg/day.
* **Titration:** Increase after one week to 10 mg/day, then up to 20 mg/day (if weight warrants).
* **For patients >30 kg:** Follow adult dosing guidelines.
## Dose Adjustments
* **Hepatic Impairment:** Reduce starting dose by 50%; adjust titration cautiously based on clinical response.
* **Renal Impairment:** Clobazam is primarily metabolized by the liver; however, caution is advised as the active metabolite (N-desmethylclobazam) may accumulate in severe impairment.
* **CYP2C19 Poor Metabolizers:** N-desmethylclobazam levels may be significantly elevated; use lower initial doses and slower titration.
## Contraindications
* Known hypersensitivity to clobazam or its components.
* History of severe hepatic impairment.
## Adverse Effects
* **Common:** Somnolence, pyrexia, lethargy, drooling (sialorrhea), constipation, respiratory tract infections.
* **Serious:** Severe skin reactions (Stevens-Johnson syndrome/TEN), respiratory depression (especially when combined with opioids), physical dependence/withdrawal symptoms if stopped abruptly, and suicidal ideation.
## Key Drug Interactions
* **CNS Depressants:** Potentiates sedative effects of alcohol, opioids, and other sedative-hypnotics; increases risk of profound sedation, respiratory depression, and death.
* **CYP2C19 Inhibitors:** (e.g., fluconazole, fluvoxamine, omeprazole) can significantly increase plasma concentrations of the active metabolite.
* **CYP2C19 Inducers:** (e.g., rifampin, St. John’s Wort) may decrease therapeutic efficacy.
* **Hormonal Contraceptives:** May decrease the effectiveness of estrogen-containing contraceptives.
## Monitoring
* **Baseline/Ongoing:** Monitor for behavioral changes, signs of depression, or suicidal ideation.
* **Skin:** Educate patients to recognize early signs of rash or severe dermatological reactions.
* **Toxicity:** Monitor for excessive somnolence or ataxia.
## Clinical Pearls
* **Dose Tapering:** Never discontinue abruptly due to the high risk of status epilepticus and withdrawal seizures; taper doses slowly over 2–4 weeks.
* **Administration:** Oral suspension and tablets can be administered without regard to food.
* **Oral Suspension:** Must be shaken well before use, and the included calibrated measuring device must be used.
* **Tolerance:** Unlike other benzodiazepines, tolerance to the anticonvulsant effects of clobazam may develop over time.
***
*Disclaimer: This information is for educational purposes only. Clinical practice guidelines and drug information can change; always verify current FDA-approved labeling and institutional protocols before prescribing or administering medication.*
